AC Immune (NASDAQ:ACIU) stock is heading higher on Monday alongside the clinical-stage biopharmaceutical company’s earnings report for the first quarter of 2024. Included in that earnings report is an operational update that covers a new collaboration agreement with Takeda Pharmaceutical (NYSE:TAK). This has Takeda Pharmaceutical signing a licensing agreement for AC Immune’s ACI-24.060. This agreement includes an upfront payment of $100 million to AC Immune. It also covers potential payments of up to$2.1 b ...